EUVIMEDEUVIMED entdecken
Crossref

Comparison of Adverse Events between Ramipril and Perindopril in Contemporary Cardiac Practice

Ramesh Sankaran, Nagendraboopathy Senguttuvan, Thoddi Ramamurthy Muralidharan, Vinodkumar Balakrishnan, Shanmugasundaram Sadhanandham, Manokar Panchanatham, Jayanthy Venkata Balasubramaniyan, Preetham Krishnamurthy, Phulgun Badimela

Annals of Clinical Cardiology · 2021

DOI: 10.4103/accj.accj_12_21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Cardiology, 2021. Verfasst von Ramesh Sankaran und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Angiotensin-converting enzyme inhibitors (ACEIs) are extensively used for the treatment and management of cardiovascular diseases. Although ACEIs are a well-tolerated medication in high percentage of patients, around 30% can develop adverse reactions like dry cough.

Objective

The objective of the study was to capture the incidence of cough in patients with cardiovascular diseases that were prescribed with perindopril and ramipril in an Indian tertiary care hospital.

Methods

In this observational study, the incidence of cough in patients with cardiovascular diseases that were prescribed with perindopril and ramipril was estimated.

Results

A total of 223 patients were enrolled in this study. Around 50.67% patients received ramipril; among them, 6.02% received 1.25 mg, 78.95% received 2.5 mg, and 13.53% received 5 mg of ramipril. Around 35.9% ( n = 80) patients received perindopril. In perindopril group, 31.3% of the patients received 2 mg dose and 68.8% of patients received 4 mg dose. Among perindopril group, the incidence of cough was observed in 10% ( n = 8) of the patients, whereas in ramipril group, it was 19.55% ( P = 0.00136). Due to cough, in perindopril group, 6.3% (5/80) of the patients discontinued treatment whereas in ramipril group, 9% (12/133) of the patients discontinued treatment medication.

Conclusions

Our study has demonstrated that perindopril has been associated with a relatively low incidence of cough compared to ramipril.

Zitieren

APA

Sankaran, R., Senguttuvan, N., Muralidharan, T. R., Balakrishnan, V., Sadhanandham, S., Panchanatham, M., Balasubramaniyan, J. V., Krishnamurthy, P., & Badimela, P. (2021). Comparison of Adverse Events between Ramipril and Perindopril in Contemporary Cardiac Practice. Annals of Clinical Cardiology. https://doi.org/10.4103/accj.accj_12_21

Vancouver

Sankaran R, Senguttuvan N, Muralidharan TR, Balakrishnan V, Sadhanandham S, Panchanatham M, et al. Comparison of Adverse Events between Ramipril and Perindopril in Contemporary Cardiac Practice. Annals of Clinical Cardiology. 2021. doi:10.4103/accj.accj_12_21

BibTeX
@article{Sankaran2021,
  author = {Sankaran, Ramesh and Senguttuvan, Nagendraboopathy and Muralidharan, Thoddi Ramamurthy and Balakrishnan, Vinodkumar and Sadhanandham, Shanmugasundaram and Panchanatham, Manokar and Balasubramaniyan, Jayanthy Venkata and Krishnamurthy, Preetham and Badimela, Phulgun},
  title = {Comparison of Adverse Events between Ramipril and Perindopril in Contemporary Cardiac Practice},
  journal = {Annals of Clinical Cardiology},
  year = {2021},
  doi = {10.4103/accj.accj_12_21}
}
Kostenlos starten →